Bromantane Dosage Guide: Protocols, Calculator & Safety

A conservative starter Bromantane protocol reflects the Russian clinical trial dosing pattern: 50 mg once daily in the morning with or shortly after breakfast for the first 3-5 days, increasing to 100 mg once daily in the morning if well tolerated, continued for a total course of 2-4 weeks followed by reassessment against baseline. The morning dose timing is important because late-day dosing risks delayed sleep onset despite the compound's generally favourable sleep profile. Splitting the 100 mg dose into 50 mg morning and 50 mg early-afternoon is an alternative pattern used by some readers who prefer more even coverage through the workday, with the caveat that the second dose should not be taken after mid-afternoon. Before starting, document baseline measures: a validated fatigue scale such as Multidimensional Fatigue Inventory or Fatigue Severity Scale, a mood and anxiety scale such as PHQ-9 and GAD-7 or equivalent, baseline sleep quality via a brief validated measure, subjective attention and motivation ratings on a simple 1-10 scale across specific domains (work task completion, social engagement, physical activity initiation), and if the reader has any cardiovascular or psychiatric history, appropriate baseline objective measures (resting heart rate, blood pressure, medication lists). More importantly, before any Bromantane trial, complete an evidence-graded workup for reversible causes of fatigue: comprehensive metabolic panel, complete blood count, iron studies including ferritin, vitamin D 25-OH, TSH and free T4, fasting glucose and HbA1c, and where indicated screening for sleep apnoea, depression, and anxiety; addressing iron deficiency, vitamin D insufficiency, hypothyroidism, sleep apnoea, or clinical depression has substantially larger effect sizes than any Bromantane trial. At week 2 and week 4 reassess the same baseline measures. A meaningful response would be a clinically relevant change in fatigue scale scores of at least 20-30% from baseline, accompanied by subjective improvement in attention, motivation, and daily function. If the first cycle produces no measurable change, Bromantane is unlikely to be meaningfully active in your case and further cycles have low expected value. If there is meaningful improvement, pause at the end of the 4-week course for at least 2-4 weeks before considering a repeat cycle, using the washout to observe whether benefits persist or fatigue returns, which helps distinguish persistent adaptation from ongoing medication dependence. Athletes should not use Bromantane regardless of how they are dosing because of WADA prohibited-substance status.

Intermediate Bromantane use in Russian clinical practice is cyclical, with 2-4 week courses at 50-100 mg daily repeated 2-3 times per year as needed during periods of increased cognitive or physical demand, seasonal fatigue, or post-infectious asthenia recovery. A typical intermediate cycle pattern is a 4-week course in late autumn to support winter energy and mood, a 4-week course in late winter or early spring, and optionally a 2-3 week supportive course during a specific stressful period such as an academic or work deadline. Continuous daily use beyond 4-6 weeks without breaks is not well supported in the Russian clinical literature and is discouraged by most practitioners familiar with the compound; the cyclical pattern allows receptor adaptation to normalise between courses and prevents chronic adaptation that might blunt response or introduce tolerance. Some users find that splitting the daily dose (50 mg morning, 50 mg early afternoon) provides smoother coverage; others find that a single 100 mg morning dose is sufficient. Combination with evidence-graded foundations matters more at this tier than in a first trial: ensure structured exercise is in place with resistance training and cardiorespiratory work, confirm sleep quality is optimised including any needed sleep apnoea treatment, address iron, vitamin D, and thyroid status, manage depression and anxiety with evidence-based pharmacotherapy and psychotherapy where indicated, and review medication lists for interactions. For readers using Bromantane for ADHD-spectrum attention complaints, a diagnostic workup by a qualified clinician remains the evidence-graded path rather than self-managing with an unregulated stimulant; if diagnosis is confirmed, prescribed medications (methylphenidate, amphetamine formulations, guanfacine, atomoxetine, or in appropriate contexts modafinil) have randomised evidence and regulated supply that Bromantane cannot match. For readers using Bromantane in context of post-viral or post-acute sequelae of infection (including long COVID), emerging evidence-based interventions such as graded exercise therapy, pacing, and where appropriate pharmacological supportive care should remain the foundation, with Bromantane positioned as exploratory adjunct in specific asthenic presentations rather than substitute. The intermediate-tier reader should have a written plan with defined cycle patterns, documented baseline measures at the start of each cycle, and an explicit off-ramp if sequential cycles fail to produce meaningful benefit or if adverse effects emerge. Competitive athletes under WADA or similar codes should remain completely abstinent regardless of cycle pattern.

Advanced Bromantane use is essentially long-term cyclical pattern use over multiple years, typically 2-4 four-week courses per year with appropriate washouts, embedded in a broader healthspan and performance framework. The key discipline at this tier is not escalating doses or extending cycle duration but rather maintaining the cyclical pattern that the compound's evidence base supports, and using the washout periods to confirm that benefits are real and that the compound is not simply masking issues that deserve other solutions. Advanced users often track responses systematically across cycles with structured journals or apps, noting dose-response patterns, cycle-duration preferences, seasonal effects, and interaction with life stressors. Integration with evidence-graded care at this tier includes comprehensive annual physical examination including cardiovascular risk assessment given dopaminergic stimulant use, blood pressure and heart rate tracking especially during cycles, occasional ECG in users with any cardiovascular history or family history, lipid panel, glucose and HbA1c, thyroid function, complete blood count, and liver function testing particularly if the reader is also using other hepatically metabolised substances; annual mental health check-ins to catch any subtle dependence patterns, mood cycling, or sleep disruption; and reassessment of whether the original indication for Bromantane use remains valid or whether the underlying issue has resolved or progressed to warrant different treatment. For athletic populations Bromantane use is categorically inconsistent with competitive sport under any code that follows WADA, and advanced users who are athletes should recognise that positive tests produce multi-year bans and reputational damage that dwarf any performance benefit. Readers considering very long-term use beyond multiple years should be explicit that long-term safety data do not exist, that the Russian pharmacology programme has not published detailed multi-year toxicology follow-up in humans, and that advanced self-experimenters are accepting unquantified long-term risk in exchange for near-term benefit; a reasonable default is to maintain the 2-3 cycles per year pattern indefinitely only if clear benefit is documented across multiple cycles, if no adverse effects have emerged, and if the user has genuinely considered evidence-graded alternatives and found them insufficient for their presentation. Advanced readers should be particularly alert to the emergence of sleep disruption, mood changes, cardiovascular symptoms, gastrointestinal issues, or cognitive changes across cycles as possible early signals of cumulative effect; persistent or progressive adverse events warrant discontinuation and appropriate evaluation rather than dose adjustment. The advanced protocol should be written, reversible, and unapologetically willing to pivot to evidence-graded alternatives if Bromantane's balance of benefit and risk shifts unfavourably over time.